Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques

Vaccine

Volumn 16, Issue 11-12, 1998, Pages 1141-1148

  Ivins, B E ^a   Pitt, M L M ^a   Fellows, P F ^a   Farchaus, J W ^a   Benner, G E ^a   Waag, D M ^a   Little, S F ^a   Anderson Jr , G W ^a   Gibbs, P H ^a   Friedlander, A M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Anthrax; Bacillus anthracis; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ANTHRAX VACCINE; ANTHRAX VACCINE ADSORBED; BACILLUS ANTHRACIS PROTECTIVE ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATIDYLCHOLINE; PHOSPHORYL LIPID A; POLYSORBATE 80; SAPONIN; SQUALENE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BACTEREMIA; CONTROLLED STUDY; DRUG EFFICACY; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0031749381     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)80112-6     Document Type: Article

References (35)

1. Puziss, M., Manning, L.C., Lynch, L.W., Barclay, E., Abelow, I. and Wright, G.G. Large-scale production of protective antigen of B. anthracis anaerobic cultures. Appl. Microbiol. 1963, 11, 330-334.
2. Puziss, M. and Wright, G.G. Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man. J. Bacteriol. 1962, 85, 230-236.
3. Brachman, P.S., Gold, H., Plotkin, S.A., Fekety, F.R., Werrin, M. and Ingraham, N.R. Field evaluation of a human anthrax vaccine. Am. J. Public Health 1962, 52, 632-645.
4. Ivins, B.E. and Welkos, S.L. Recent advances in the development of an improved human anthrax vaccine. Eur. J. Epidemiol. 1988, 4, 12-19.
5. Ivins, B.E., Fellows, P.F., Pitt, M.L.M., Estep, J.E., Welkos, S.L., Worsham, P.L. and Friedlander, A.M. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. In: Proceedings of the International Workshop on Anthrax, 19-21 September 1995, Winchester, UK. Salisbury Medical Bulletin, Special Suppl. no. 87, 1996, pp. 125-126
6. Turnbull, P.C.B., Quinn, C.P., Hewson, R., Stockbridge, M.C. and Melling, J. Protection conferred by microbially-supplemented UK and purified PA vaccines. In: Proceedings of the International Workshop on Anthrax, 11-13 April 1989, Winchester, UK. Salisbury Medical Bulletin, Special Suppl. no. 68, 1990, pp. 89-91
7. Turnbull, P.C.B., Leppla, S.H., Broster, M.G. and Melling, J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective antigen. Med. Microbiol. Immunol. 1988, 177, 293-303.
8. Turnbull, P.C.B. Anthrax vaccines: past, present and future. Vaccine 1991, 9, 533-539.
9. Hambleton, P. and Turnbull, P.C.B. Anthrax vaccine development: a continuing story. In: Bacterial Vaccines. Advances in Biotechnological Processes (Ed. Mizrahi, A.). Vol 13, Alan R. Liss, New York, 1990, pp. 105-122
10. Welkos, S., Becker, D., Friedlander, A. and Trotter, R. Pathogenesis and host resistance to Bacillus anthracis: a mouse model. In: Proceedings of the International Workshop on Anthrax, 11-13 April 1989, Winchester, UK. Salisbury Medical Bulletin, Special Suppl. no. 68, 1990, pp. 49-52
11. Ivins, B.E., Welkos, S.L., Little, S.F., Crumrine, M.H. and Nelson, G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 1992, 60, 662-668.
12. Ivins, B., Fellows, P., Pitt, L., Estep, J., Farchaus, J., Friedlander, A. and Gibbs, P. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 1995, 13, 1779-1784.
13. Edelman, R. and Tacket, C.O. Adjuvants. Intern. Rev. Immunol. 1990, 7, 51-66.
14. Myers, K.R. and Gustafson, G.L. Adjuvants for human vaccine usage: a rational design. In: Vaccines and Immune-therapy (Ed Cryz, S.J., Jr.). Pergamon Press, New York, 1991, pp. 404-411
15. Allison, A.C. and Byars, N.E. Immunological adjuvants and their mode of action. Biotechnology 1992, 20, 431 -449.
16. Kensil, C.R., Patel, U., Lennick, M. and Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J. Immunol. 1991, 146, 431-437.
17. Kensil, C.R., Newman, M.J., Coughlin, R.T., Soltysik, S., Bedore, D., Recchia, J., Wu, J.Y. and Marciani, D.J. The use of Stimulon adjuvant to boost vaccine response. Vaccine Res. 1993, 2, 273-281.
18. Ribi, E., Cantrell, J. and Yakayama, K. A new immunomodulator with potential clinical applications: monophosphoryl lipid A, a detoxified endotoxin. Immunol. Newslett. 1985, 6, 33-36.
19. Ribi, E., Ulrich, J.T. and Masihi, K.N. Immunopotentiating activities of monophosphoryl lipid A. In: Immunopharmacology of Infectious Disease. Vaccine Adjuvants and Modulators of Non-Specific Resistance Progress in Leukocyte Biology, (Ed Majde, J.A.). Vol. 6, Alan R. Liss, New York, 1987, pp. 101-112
20. Friedlander, A.M., Welkos, S.L., Pitt, M.L.M., Ezzell, J.W., Worsham, P.L., Rose, K.J., Ivins, B.E., Lowe, J.R., Howe, G.B., Mikesell, P. and Lawrence, W.B. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 1993, 167, 1239-1242.
21. Pitt, M.L.M., Ivins, B., Estep, J.E., Farchaus, J. and Friedlander, A.M. Comparative efficacy of a recombinant protective antigen vaccine against inhalation anthrax in guinea pigs, rabbits, and rhesus monkeys. Abstracts of the Annual Meeting of the American Society for Microbiology 1996, E-70, 278
22. Dulbecco, R. and Vogt, M. Plaque formation and isolation of pure lines with poliomyelitis viruses. J. Exp. Med. 1954, 99, 167-182.
23. Little, S.F. and Knudson, G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun. 1986, 52, 509-512.
24. -) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 1990, 58, 303-308.
25. Leighton, T.J. and Doi, R.H. The stability of messenger ribonucleic acid during sporulation in Bacillus subtilis. J. Biol. Chem. 1971, 246, 3189-3195.
26. May, K.R. The Collison nebulizer, description, performance and applications. J. Aerosol. Sci. 1973, 4, 235-243.
27. Cown, W.B., Kethley, T.W. and Fincher, E.L. The critical orifice liquid impinger as a sampler for bacterial aerosols. Appl. Microbiol. 1957, 5, 119-124.
28. Green, L.M., Reade, J.L. and Ware, C.F. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J. Immunol. Meth. 1984, 56, 1066-1069.
29. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 1983, 65, 55-63.
30. Little, S.F., Leppla, S.H. and Friedlander, A.M. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis. Infect. Immun. 1990, 56, 1807-1813.
31. Hansen, M.B., Nielsen, S.E. and Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Meth. 1989, 119, 203-210.
32. Iacono-Connors, L.C., Novak, J., Rossi, C., Mangiafico, J. and Ksiazek, T. Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protec-tive antigen (PA): measurement of human anti-PA antibodies. Clin. Diag. Lab. Immunol. 1994, 1, 78-82.
33. Welkos, S.L. and Friedlander, A.M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 1988, 5, 127-139.
34. Coulson, N.M., Fulop, M. and Titball, R.W. Bacillus anthracis protective antigen expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine 1994, 12, 1395-1401.
35. Pezard, C., Weber, M., Sirard, J., Berche, P. and Mock, M. Protective immunity induced by Bacillus anthracis toxindeficient strains. Infect. Immun. 1995, 63, 1369-1372.